Publications by authors named "Bruce Cree"

Claim this Profile
R
Reply to "New Horizons for Multiple Sclerosis Therapy: 2025 and Beyond".
Joseph J Sabatino, Bruce A C Cree, Stephen L Hauser

Ann Neurol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Final analysis of the DAYBREAK open-label extension trial.
Krzysztof W Selmaj, Lawrence Steinman, Giancarlo Comi, Amit Bar-Or, Douglas L Arnold, Bruce Ac Cree

Mult Scler· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validating wearable step counts in multiple sclerosis research: a replication study.
Myla D Goldman, Shanshan Chen, Bhavana Kunisetty, Jeffrey M Gelfand, Bruce A C Cree

Front Neurol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blood biomarkers for predicting disability worsening in progressive multiple sclerosis: a multinational, individual participant-level analysis.
Ahmed Abdelhak, Franziska Bachhuber, Kiarra Ning, Pascal Benkert, W John Boscardin, Bruce Ac Cree

J Neurol Neurosurg Psychiatry· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-Dose Pulse Glucocorticoid Treatment Prevents White Matter Spinal Cord Pseudoatrophy in Newly Diagnosed Multiple Sclerosis.
Simone Sacco, Nico Papinutto, Vinicius A Schoeps, Shuiting Cheng, William A Stern, Bruce A C Cree

Ann Neurol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Myelin injury precedes axonal injury and symptomatic onset in multiple sclerosis.
Ahmed Abdelhak, Gabriel Cerono, Fahime Sheikhzadeh, Adil Harroud, Kiarra Ning, Bruce A C Cree

Nat Med· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigating the impact of age on neurodegeneration after optic neuritis in multiple sclerosis using optical coherence tomography.
Henriette Km Reinsberg, Frederike C Oertel, Daniel Casillas, Gelsomina Kaufhold, Shivany Condor Montes, Bruce A Cree

Mult Scler· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Performance of Composite Endpoints Defining Progression Independent of Relapse Activity in Multiple Sclerosis.
Ludwig Kappos, Sean Yiu, Jason Reucassel, Jiwon Oh, Cristina Granziera, Bruce A C Cree

Ann Clin Transl Neurol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brain atrophy and associations with long-term disability and cognitive function in participants with relapsing multiple sclerosis treated with ozanimod: Results from phase 3 and open-label extension trials.
Jeffrey A Cohen, Douglas L Arnold, John DeLuca, Hans-Peter Hartung, Ludwig Kappos, Bruce Ac Cree

Mult Scler· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Studies to Assess the Safety and Efficacy of Elezanumab when Added to Standard of Care in Relapsing and Progressive Forms of Multiple Sclerosis.
Bruce A C Cree, Mark S Freedman, Michael Gold, Kimberly Pfleeger, Brittany Schwefel

Ann Neurol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Frequency and Diagnostic Implications of Paramagnetic Rim Lesions in People Presenting for Diagnosis to a Multiple Sclerosis Clinic.
Brian Renner, Elizabeth Daphne Verter, Martina Absinta, Lynn Daboul, Praneeta Raza, Bruce Anthony Campbell Cree

Neurology· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative Safety Profiles of Ocrelizumab and Rituximab in Multiple Sclerosis Treatment Using Real-World Evidence.
Gabriel Cerono, Bruce A C Cree, Stephen L Hauser, Sergio E Baranzini

Ann Neurol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New Horizons for Multiple Sclerosis Therapy: 2025 and Beyond.
Joseph J Sabatino, Bruce A C Cree, Stephen L Hauser

Ann Neurol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HLA-A∗03:01 as predictive genetic biomarker for glatiramer acetate treatment response in multiple sclerosis: a retrospective cohort analysis.
Brian C Zhang, Tilman Schneider-Hohendorf, Rebecca Elyanow, Beatrice Pignolet, Simon Falk, Bruce A C Cree

EBioMedicine· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: The Evolution of Anti‑CD20 Treatment for Multiple Sclerosis: Optimization of Antibody Characteristics and Function.
Bruce A C Cree, Joseph R Berger, Benjamin Greenberg

CNS Drugs· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Update on novel multiple sclerosis treatments: from dismal defeat to scintillating success.
Bruce Cree, Hans-Peter Hartung

Curr Opin Neurol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Evolution of Anti-CD20 Treatment for Multiple Sclerosis: Optimization of Antibody Characteristics and Function.
Bruce A C Cree, Joseph R Berger, Benjamin Greenberg

CNS Drugs· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glial Fibrillary Acidic Protein as a Marker of Disease in Relapsing Multiple Sclerosis: Post Hoc Analysis of Phase 3 Ozanimod Trials.
Sarah Harris, Giancarlo Comi, Bruce A C Cree, Douglas L Arnold, Lawrence Steinman

Eur J Neurol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis.
Jiwon Oh, Douglas L Arnold, Bruce A C Cree, Carolina Ionete, Ho Jin Kim

N Engl J Med· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
No evidence of fluctuations in daily step count between infusions in people with multiple sclerosis treated with anti-CD20 monoclonal antibodies.
Valerie J Block, Kyra Henderson, Shane Poole, Gabby B Joseph, Jeffrey M Gelfand, Bruce Ac Cree

Mult Scler J Exp Transl Clin· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of siponimod on retinal thickness, a marker of neurodegeneration, in participants with SPMS: Findings from the EXPAND OCT substudy.
Patrick Vermersch, Ralf Gold, Amit Bar-Or, Bruce A C Cree, Robert J Fox

Mult Scler Relat Disord· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Treatment With Ocrelizumab in Patients With Early-Stage Relapsing MS: Nine-Year Data From the OPERA Studies Open-Label Extension.
João J Cerqueira, Achim Berthele, Bruce A C Cree, Massimo Filippi, Gabriel Pardo

Neurology· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Menopause With Functional Outcomes and Disease Biomarkers in Women With Multiple Sclerosis.
Hannah E Silverman, Alan Bostrom, Alyssa N Nylander, Amit Akula, Ann A Lazar, Bruce Anthony Campbell Cree

Neurology· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reliability of Central Vein Sign Imaging With 3T FLAIR* in a Multicenter Study.
Melissa Lynne Martin, Quy Cao, Elaina Luskin, Brian Renner, Lynn Daboul, Bruce A C Cree

J Neuroimaging· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A data-driven model of disability progression in progressive multiple sclerosis.
Sara Garbarino, Carmen Tur, Marco Lorenzi, Matteo Pardini, Michele Piana, Bruce A C Cree

Brain Commun· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis